
Lower-dose abiraterone offers viable alternative to standard-dose for mCRPC
Lower-dose abiraterone acetate (Zytiga) demonstrated comparable efficacy to standard-dose abiraterone, offering a viable alternative for patients with metastatic castration-resistant prostate cancer (mCRPC), according to phase 3 data presented at the 2025 …